GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TDS Pharm Co Ltd (XKRX:464280) » Definitions » Free Cash Flow

TDS Pharm Co (XKRX:464280) Free Cash Flow : ₩3,022 Mil (TTM As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is TDS Pharm Co Free Cash Flow?

TDS Pharm Co's total free cash flow for the six months ended in Dec. 2023 was ₩3,022 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩3,022 Mil.

TDS Pharm Co's Free Cash Flow per Share for the six months ended in Dec. 2023 was ₩709.79. Its free cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩709.79.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of TDS Pharm Co was 30.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -66.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.

During the past 4 years, TDS Pharm Co's highest 3-Year average Free Cash Flow per Share Growth Rate was -66.20% per year. The lowest was -66.20% per year. And the median was -66.20% per year.


TDS Pharm Co Free Cash Flow Historical Data

The historical data trend for TDS Pharm Co's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TDS Pharm Co Free Cash Flow Chart

TDS Pharm Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Free Cash Flow
1,831.21 3,478.92 2,311.54 3,022.30

TDS Pharm Co Semi-Annual Data
Dec20 Dec21 Dec22 Dec23
Free Cash Flow 1,831.21 3,478.92 2,311.54 3,022.30

TDS Pharm Co Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

TDS Pharm Co's Free Cash Flow for the fiscal year that ended in Dec. 2023 is calculated as

Free Cash Flow (A: Dec. 2023 )=Cash Flow from Operations+Capital Expenditure
=3293.664+-271.368
=3,022

TDS Pharm Co's Free Cash Flow for the quarter that ended in Dec. 2023 is calculated as

Free Cash Flow (Q: Dec. 2023 )=Cash Flow from Operations+Capital Expenditure
=3293.664+-271.368
=3,022

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩3,022 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TDS Pharm Co  (XKRX:464280) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Dec23, TDS Pharm Co's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Dec23)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0+0
=0 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


TDS Pharm Co Free Cash Flow Related Terms

Thank you for viewing the detailed overview of TDS Pharm Co's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


TDS Pharm Co Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.

TDS Pharm Co Headlines

No Headlines